Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 15.09.2025 1 Am J Clin Pathol 1 Am J Surg 3 Ann Surg Oncol 1 Ann Thorac Surg 2 Cancer 2 Cancer Cell 1 Cancer Lett 1 Cancer Res 1 Carcinogenesis 2 Chest 1 Clin Cancer Res 1 Clin Lung Cancer 1 Eur J Cardiothorac Surg 1 Int J Cancer 2 Int J Radiat Oncol Biol Phys 2 J Cancer Res Clin Oncol 1 J Clin Oncol 2 J Natl Cancer Inst 8 J Thorac Oncol 1 Lancet 1 Lancet Oncol 11 Lung Cancer 1 Mol Cancer Ther 1 Nat Genet 5 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Pathol

1. BHATTARAI N, Cook JR
   IRTA1 expression in extranodal marginal zone (MALT) lymphoma is variable across anatomic sites.
   Am J Clin Pathol. 2025 Jun 30:aqaf056. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Am J Surg

2. SARFRAZ A, Khalil M, Rashid Z, Altaf A, et al
   Racial/ethnic and socioeconomic disparities in cancer mortality hotspots: A multi-state geospatial analysis.
   Am J Surg. 2025;248:116492.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. SONODA D, Kondo Y, Maruyama R, Mitsuhashi S, et al
   ASO Author Reflections: Impact of the Epidermal Growth Factor Receptor Exon 20 Q787Q Mutation on the Clinical Course of Non-Small-Cell Lung Cancer.
   Ann Surg Oncol. 2025 Sep 10. doi: 10.1245/s10434-025-18270.
   PubMed        
   
   
4. XIAO W, Chen X
   ASO Author Reflections: RUNX3 in Non-Small Cell Lung Cancer Tumor Microenvironment: Bridging Mechanisms and Clinical Potential.
   Ann Surg Oncol. 2025 Sep 8. doi: 10.1245/s10434-025-18187.
   PubMed        
   
   
5. XIAO W, Zheng J, Deng Y, Huang B, et al
   Single-Cell RNA Sequencing Reveals Potential Mechanism of RUNX3 Reshaping Tumor Microenvironment in Non-small-cell Lung Cancer.
   Ann Surg Oncol. 2025 Sep 7. doi: 10.1245/s10434-025-18034.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

6. SERVAIS EL
   Defining Success in Synchronous Primary Early Lung Cancer: Recurrence Matters.
   Ann Thorac Surg. 2025 Sep 5:S0003-4975(25)00855.
   PubMed        
   
   

   
   Cancer

7. FATHI JT, Cinciripini PM, DePrimo MJ, Houston TP, et al
   The American Cancer Society National Lung Cancer Roundtable strategic plan: Tobacco treatment in the context of lung cancer screening.
   Cancer. 2025;131:e35972.
   PubMed         Abstract available
   
   
8. COOPER AJ, Garbo E, Arfe A, Conroy M, et al
   Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.
   Cancer. 2025;131:e70081.
   PubMed         Abstract available
   
   

   
   Cancer Cell

9. HE D, Wu Q, Tian P, Liu Y, et al
   Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps.
   Cancer Cell. 2025;43:1622-1636.
   PubMed         Abstract available
   
   
10. SATPATHY S, Clark NM, Chen YJ, Hosseini N, et al
    Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures.
    Cancer Cell. 2025;43:1731-1757.
    PubMed         Abstract available
    
    

    
    Cancer Lett

11. XU Y, Chen M, Gao X, Liu X, et al
    Efficacy and safety of sunvozertinib monotherapy as first-line treatment in NSCLC patients with EGFR exon 20 insertion mutations: A phase 2, single-center trial.
    Cancer Lett. 2025;630:217904.
    PubMed         Abstract available
    
    

    
    Cancer Res

12. CAO G, Ma L, Wang X, Li G, et al
    Interaction and Reciprocal Stabilization of H3.3 and PARP1 Promotes DNA Damage Repair and Tumor Progression in Small Cell Lung Cancer.
    Cancer Res. 2025 Sep 12. doi: 10.1158/0008-5472.CAN-24-4245.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

13. HOU G, Lu Z, Zeng D, Chen Q, et al
    Longitudinal single-cell RNA model aids prediction of EGFR-TKI resistance.
    Carcinogenesis. 2025;46:bgaf038.
    PubMed         Abstract available
    
    

    
    Chest

14. KIM RY
    The Association of Lung Cancer Screening Centralization With Annual Adherence Rates.
    Chest. 2025;168:572-573.
    PubMed        
    
    
15. WERNLI KJ, Anderson ML, Palazzo L, Luce C, et al
    Effectiveness of health communication intervention to improve knowledge on timeliness to return for annual lung cancer screening: The Larch Trial.
    Chest. 2025 Sep 10:S0012-3692(25)05173-6. doi: 10.1016/j.chest.2025.07.4111.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

16. CHEN PW, Minocha M, Kong S, Jiang T, et al
    Tarlatamab exposure-efficacy and exposure-safety relationships to inform dose selection in patients with small cell lung cancer (SCLC).
    Clin Cancer Res. 2025 Sep 10. doi: 10.1158/1078-0432.CCR-25-2134.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

17. GUAY CA, Suhani A, Perreault L, Mai V, et al
    The Changing Landscape of Lung Cancer Resection Outcomes Over the Past two Decades.
    Clin Lung Cancer. 2025 Aug 13:S1525-7304(25)00189.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

18. XU Y, Wang Z, Tao Y, Zhang J, et al
    Ground-Glass Opacity Component as a Protective Factor for Patients With Invasive Adenocarcinoma
    Eur J Cardiothorac Surg. 2025;67:ezaf285.
    PubMed         Abstract available
    
    

    
    Int J Cancer

19. XU Y, Zhang Q, Gao J, Yao S, et al
    Effects of immune checkpoint inhibitors on the pulmonary circulation in lung cancer patients.
    Int J Cancer. 2025 Sep 5. doi: 10.1002/ijc.70110.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

20. KNOTH J, Nout RA, Potter R, Mahantshetty DU, et al
    Distant metastasis after chemoradiation and IGABT in locally advanced cervical cancer.
    Int J Radiat Oncol Biol Phys. 2025 May 10:S0360-3016(25)00436.
    PubMed         Abstract available
    
    
21. MORRIS T, Muradova Z, Brown N, Carmes L, et al
    Second-Generation Gadolinium-Bismuth Ultrasmall Nanoparticles Amplify the Effects of Clinical Radiation Therapy and Provide Clinical Magnetic Resonance Imaging Contrast.
    Int J Radiat Oncol Biol Phys. 2025;123:572-582.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

22. SHI Y, Zhao D, Xiao Z, Wang Y, et al
    The impact of miRNAs on epithelial-mesenchymal transition in lung cancer and the latest advances in their use as diagnostic markers.
    J Cancer Res Clin Oncol. 2025;151:252.
    PubMed         Abstract available
    
    
23. KASTNER A, Kron A, Eilers L, Spier A, et al
    DigiNet: Optimizing personalized care for patients with stage IV non-small cell lung cancer (NSCLC) through a digitally connected provider network-analysis plan of a prospective multicenter cohort trial.
    J Cancer Res Clin Oncol. 2025;151:244.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

24. YANG JC, Wang M, Doucet L, Fan Y, et al
    Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
    J Clin Oncol. 2025 Sep 9:JCO2500788. doi: 10.1200/JCO-25-00788.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

25. FAN Y, Jin R, Monterroza L, Liu X, et al
    Suppression of LKB1-mutant lung adenocarcinoma by natural killer cells from females.
    J Natl Cancer Inst. 2025;117:1858-1867.
    PubMed         Abstract available
    
    
26. HAAS JS, Todd KW, Mclerran D, Tiro JA, et al
    Gaps in care across the cancer screening continuum for cervical, colorectal and lung cancer.
    J Natl Cancer Inst. 2025 Sep 10:djaf248. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

27. PARK S, Ahn HK, Lee S, Min YJ, et al
    Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.
    J Thorac Oncol. 2025;20:1279-1288.
    PubMed         Abstract available
    
    
28. KIM H, Jo E, Kim J, Jang SH, et al
    Screening-Detected versus Interval Lung Cancer in the Biennial Korean National Lung Cancer Screening Program: Proportion, Characteristics, and Mortality.
    J Thorac Oncol. 2025 Sep 4:S1556-0864(25)01038.
    PubMed         Abstract available
    
    
29. DE GROOT P, Erasmus J, Vlahos I
    Lung Cancer Screening: Future Opportunities.
    J Thorac Oncol. 2025;20:1152-1155.
    PubMed        
    
    
30. LEONG TL, Steinfort DP
    Broadening the Scope of Bronchoscopic Sampling in the Era of Minimally Invasive and Molecular Diagnosis of Lung Cancer.
    J Thorac Oncol. 2025;20:1172-1176.
    PubMed        
    
    
31. RODE MM, Midthun DE
    A Response to the Letter to the Editor: Cost-Efficiency of Risk-Based Lung Cancer Screening Across PLCOm2012 Risk Deciles.
    J Thorac Oncol. 2025;20:e100-e101.
    PubMed        
    
    
32. CARBONE DP, Hirsch FR, Osarogiagbon RU, Nishimura KK, et al
    The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database.
    J Thorac Oncol. 2025 Jul 28:S1556-0864(25)00813.
    PubMed         Abstract available
    
    
33. ENG L, Evans WK, Eisele M, Nishimura KK, et al
    The International Association for the Study of Lung Cancer Staging Project: The Impact of Smoking Status on Lung Cancer Staging in the Ninth Edition of the TNM Classification.
    J Thorac Oncol. 2025 Aug 4:S1556-0864(25)00824.
    PubMed         Abstract available
    
    
34. CHEN CC, Chen SC
    Cost-Efficiency of Risk-Based Lung Cancer Screening Across PLCOm2012 Risk Deciles.
    J Thorac Oncol. 2025;20:e99-e100.
    PubMed        
    
    

    
    Lancet

35. PRAMESH CS, Kelly K, Hunter DJ, Coelho Wisdom V, et al
    The IASLC-Lancet Commission: a transformative global approach to lung cancer.
    Lancet. 2025 Sep 7:S0140-6736(25)01719-2. doi: 10.1016/S0140-6736(25)01719.
    PubMed        
    
    

    
    Lancet Oncol

36. PAULSON KG, Lau SCM, Ahn MJ, Moskovitz M, et al
    Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.
    Lancet Oncol. 2025 Sep 8:S1470-2045(25)00480.
    PubMed         Abstract available
    
    

    
    Lung Cancer

37. UTSUMI H, Yagishita S, Kawajiri K, Torasawa M, et al
    Identification of poor prognostic factors using circulating extracellular vesicles in durvalumab consolidation therapy for locally advanced non-small cell lung cancer.
    Lung Cancer. 2025;208:108732.
    PubMed         Abstract available
    
    
38. CIAMMELLA P, Iori F, Borghetti P, Galaverni M, et al
    Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial).
    Lung Cancer. 2025;207:108718.
    PubMed         Abstract available
    
    
39. JIANG Y, Lin Y, Mo L, Deng H, et al
    Real-time non-invasive localization in sub-lobar resection for small pulmonary nodules: a noninferiority randomized clinical trial.
    Lung Cancer. 2025;207:108724.
    PubMed         Abstract available
    
    
40. ONO S, Taniguchi H, Kuroda K, Hashimoto T, et al
    Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab.
    Lung Cancer. 2025;207:108709.
    PubMed         Abstract available
    
    
41. TRUDU L, Rovesti G, Neri G, Pugliese G, et al
    CAR-T for Lung Cancers: Challenges and Innovations.
    Lung Cancer. 2025;207:108711.
    PubMed         Abstract available
    
    
42. ZHANG Y, Dai X, Liang J, Yang C, et al
    Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns.
    Lung Cancer. 2025;207:108715.
    PubMed         Abstract available
    
    
43. ALAY A, Marin R, Aliagas E, Gausachs M, et al
    Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma.
    Lung Cancer. 2025;207:108679.
    PubMed         Abstract available
    
    
44. SHAH R, Buchmeier EL, Kopp HG, Christoph DC, et al
    First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study.
    Lung Cancer. 2025;207:108702.
    PubMed         Abstract available
    
    
45. WANG R, Wei H, Qu C, Bai Y, et al
    Unlocking the potential: tissue mutation abundance as a predictor for third-generation EGFR-TKI efficacy in NSCLC.
    Lung Cancer. 2025;207:108699.
    PubMed         Abstract available
    
    
46. KALCHIEM-DEKEL O, Rakocevic R, Toumbacaris N, Tan KS, et al
    Robotic-assisted bronchoscopy for histopathologic subtyping of primary lung adenocarcinoma.
    Lung Cancer. 2025;207:108681.
    PubMed         Abstract available
    
    
47. PROVENCIO M, Cobo M, Rodriguez-Abreu D, Carcereny E, et al
    Biomarker landscape in advanced NSCLC: insights from a national prospective registry.
    Lung Cancer. 2025;207:108680.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

48. BUSENBENDER T, Pelageev DN, Hauschild J, Kaune M, et al
    6-[(1,4-Naphthoquinone-2-yl)methyl]thio-Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer.
    Mol Cancer Ther. 2025;24:1331-1349.
    PubMed         Abstract available
    
    

    
    Nat Genet

49. GIMENO-VALIENTE F, Castignani C, Larose Cadieux E, Mensah NE, et al
    DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution.
    Nat Genet. 2025;57:2226-2237.
    PubMed         Abstract available
    
    

    
    PLoS One

50. WANG L, Zhao H, Yang K, Wang Z, et al
    Assessing the real-world safety of docetaxel for non-small cell lung cancer: Insights from a comprehensive analysis of FAERS data.
    PLoS One. 2025;20:e0331979.
    PubMed         Abstract available
    
    
51. DAI L, Hu J, Yang Y, Qian B, et al
    1p-Enh-regulated CYP4B1 alleviates NNK-induced heart failure and lung cancer via the STAT3 pathway.
    PLoS One. 2025;20:e0331471.
    PubMed         Abstract available
    
    
52. JUNG DM, Kwon YJ, Cho YW, Baek JG, et al
    A volumetric modulated arc therapy-based dynamic conformal arc technique with limited monitor units (VMATliMU) to reduce multileaf collimator interplay effects: A computational phantom study for stage I non-small-cell lung cancer.
    PLoS One. 2025;20:e0332190.
    PubMed         Abstract available
    
    
53. NAM AY, Joo SH, Lee NY, Yoon G, et al
    3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth.
    PLoS One. 2025;20:e0329706.
    PubMed         Abstract available
    
    
54. ZHAO W, Zhao Z, Wang Y, Yang H, et al
    Artificial intelligence-based CT histogram parameters differentiating bronchiolar adenoma and lung adenocarcinomas: A two-center study.
    PLoS One. 2025;20:e0331336.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.